Drugs / Alpha-Lactalbumin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07629895 | Sep 2026 → Apr 2027 expected | polycystic ovary syndrome | Quaid-e-Azam Medical College | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-Lactalbumin | “Alpha-lactalbumin 50 mg administered orally twice daily in combination with myo-inositol for 12 weeks.” NCT07629895 ↗ |
| Known as | α-lactalbumin | “The combination with the milk protein α-lactalbumin can be a useful therapeutic approach to overcome inositol resistance and achieve ovulation in these women.” PMID 37367875 ↗ May 2023 |
| Modality | Protein / enzyme biologic | “Alpha-lactalbumin, a whey protein fraction, has been reported to enhance intestinal absorption and bioavailability of myo-inositol, potentially leading to improved therapeutic outcomes.” NCT07629895 ↗ |
| Route | Oral | “Alpha-lactalbumin 50 mg administered orally twice daily in combination with myo-inositol for 12 weeks.” NCT07629895 ↗ |